Blog

The India cardiovascular devices market is projected to grow from USD 2,075.98 million in 2024 to an estimated USD 4,580.91 million based on 2032, with a compound annual growth rate (CAGR) 9.2% from 2025 to 2032. This growth reflects a robust demand for advanced cardiovascular solutions across both public and private healthcare sectors.

Key market drivers include a growing elderly population, lifestyle changes leading to higher cardiovascular risks, and increasing access to health insurance and affordable care. The government’s focus on expanding healthcare coverage under initiatives such as Ayushman Bharat and the promotion of indigenous medical device manufacturing under the “Make in India” program are further enhancing market accessibility and affordability. Technological advancements, particularly in interventional cardiology and remote monitoring, continue to shape the market’s evolution.

Regionally, metropolitan cities such as Delhi, Mumbai, Chennai, and Bengaluru lead in terms of cardiovascular device adoption due to higher awareness, better infrastructure, and specialized cardiac centers. However, tier-2 and tier-3 cities are witnessing rapid improvements in healthcare delivery, widening the market reach. Key players operating in the India cardiovascular devices market include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, GE HealthCare, and Philips India, all of which are actively expanding their product portfolios and local partnerships.

Market drivers
Rising prevalence of cardiovascular diseases and associated risk factors
India is witnessing a sharp increase in the prevalence of cardiovascular diseases (CVDs), which has become a major public health concern. The burden of ischemic heart disease, stroke, and heart failure has surged due to sedentary lifestyles, poor dietary habits, smoking, excessive alcohol consumption, and rising obesity rates. For instance, according to the World Health Organization (WHO), cardiovascular diseases accounted for 27% of total deaths in India in 2016, making them the leading cause of mortality. Additionally, the Indian Council of Medical Research (ICMR) reports that CVDs contribute significantly to the country’s disease burden. Urbanization has accelerated this trend, as it brings with it lifestyle transitions that elevate cardiovascular risk. This rising disease burden has spurred significant demand for a wide range of cardiovascular devices, including diagnostic equipment, interventional tools such as angioplasty catheters and stents, implantable devices like pacemakers and defibrillators, and monitoring solutions. The increasing incidence of comorbid conditions such as diabetes and hypertension further exacerbates cardiovascular risks, prompting early screening and continuous monitoring. As the disease pattern shifts toward non-communicable diseases, healthcare providers are adopting advanced cardiovascular technologies to manage patient outcomes effectively, thereby strengthening the market demand for innovative devices.

Government initiatives and growing healthcare infrastructure
The Indian government’s strategic focus on healthcare access and affordability has significantly boosted the cardiovascular devices market. Programs such as Ayushman Bharat, the world’s largest publicly funded health insurance scheme, have brought advanced cardiac treatments within reach for millions. For instance, the National Health Mission and the expansion of government-funded tertiary care hospitals are further strengthening infrastructure for non-communicable disease management. Simultaneously, the Pradhan Mantri Jan Arogya Yojana (PM-JAY) supports the reimbursement of cardiac procedures, including surgeries and implants, thereby driving demand for devices. Moreover, government incentives under the Production Linked Incentive (PLI) scheme and the Make in India initiative have encouraged domestic manufacturing of medical devices, including cardiovascular solutions. This reduces reliance on imports and makes devices more accessible and cost-effective. Several state governments have also partnered with private healthcare players to expand diagnostic and interventional cardiology services in underserved regions. Collectively, these policy efforts and investments have not only enhanced the availability of cardiovascular care but have also fueled robust market growth for related devices.

Technological advancements and product innovation
Rapid technological advancements in cardiovascular diagnostics and therapeutics have revolutionized patient care and propelled market expansion in India. The development of minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR), drug-eluting stents (DES), and image-guided interventions, has made complex cardiac treatments saf

The India malaria diagnostics market is projected to reach approximately USD 92.7 billion by 2034, rising from USD 59.2 billion in 2024. This reflects a compound annual growth rate (CAGR) of 4.5% during the forecast period. The expansion is driven by ongoing government initiatives, technology innovation in diagnostics, and rising public awareness. The Indian government’s efforts toward malaria elimination continue to boost demand for efficient diagnostic services. This includes early detection programs and wider availability of diagnostic infrastructure across public healthcare settings. These initiatives aim to reduce malaria-related morbidity and improve overall public health outcomes.

A key driver for this market is the continuous advancement in diagnostic technology. The availability of rapid diagnostic tests (RDTs) has significantly improved the accuracy and speed of malaria detection. These tools are especially useful in remote and underserved areas, where laboratory access is limited. Portable RDTs have made timely diagnosis possible without the need for complex lab facilities. Moreover, the integration of digital diagnostic tools and mobile health solutions is supporting better monitoring and reporting. These innovations not only improve healthcare access but also enable faster treatment decisions, contributing to better disease control.

Public awareness and education efforts are also playing a significant role in boosting the malaria diagnostics market. Various campaigns by health departments and non-governmental organizations have emphasized the importance of early diagnosis and prevention. As a result, more individuals are seeking testing when symptoms arise. Increased awareness has also led to better utilization of diagnostic resources at both urban and rural levels. This shift in healthcare-seeking behavior is helping to curb malaria transmission through earlier intervention and treatment.

International support further strengthens the malaria diagnostics infrastructure in India. Collaborations with the World Health Organization (WHO), Global Fund, and other global health agencies have enabled access to technical expertise and funding. These partnerships assist in deploying best practices and ensuring the supply of advanced diagnostic kits. Additionally, capacity-building initiatives and training for health workers have improved diagnostic accuracy and reporting. Such support is essential in sustaining India’s long-term malaria control strategy.

The growth of the malaria diagnostics market in India is underpinned by strong government action, rapid technological progress, rising health awareness, and international cooperation. These combined efforts support India’s goal to eliminate malaria and improve disease surveillance. The diagnostics sector will continue to play a central role in this nationwide public health mission.

In conclusion, the India malaria diagnostics sector is growing steadily due to strong support from government programs, global partnerships, and new technologies. The use of rapid and digital diagnostic tools is helping reach more people, especially in rural and hard-to-access areas. Hospitals and mobile health units are playing a vital role in early detection and treatment. Awareness campaigns and education have encouraged more people to seek timely diagnosis, helping reduce the spread of the disease. Research institutions are also working to improve the accuracy and speed of testing methods. These combined efforts are making diagnostics a central part of India’s strategy to eliminate malaria and improve public health outcomes. Market.us

The US health secretary, Robert F Kennedy Jr, refused to say whether he would vaccinate his children if he had to choose today, and defended Republicans’ proposal to cut healthcare to fund tax cut extensions.

Kennedy’s back-to-back testimonies before House and Senate committees were his first appearances before lawmakers since his confirmation in February. The secretary was called to discuss Donald Trump’s proposed budget, which would impose disproportionately large cuts to scientific enterprises at the health department.

However, the most memorable exchange went to a deeper tension between Kennedy and his own department – his contradictory and at times inflammatory statements on vaccines.

“If you had a child today, would you vaccinate that child for measles?” began the Democratic congressman Mark Pocan of Wisconsin at the House appropriations committee hearing.

“For measles? Um, probably for measles,” said Kennedy, in one of the few hesitations of the hearing. “What I would say is my opinions about vaccines are irrelevant … I don’t want to seem like I’m being evasive, but I don’t think people should be taking advice, medical advice, from me.”

Vaccines are considered one of public health’s greatest victories, and the measles vaccine alone is estimated to have saved 90 million lives in five decades. The US is in the midst of the single worst measles outbreak since 2000. Three people, including two unvaccinated children, have died in Texas. Before heading the health department, Kennedy led arguably the most influential anti-vaccine campaign group in the nation.

Pocan went on to ask about chickenpox.

“Um, again, I don’t want to give advice,” Kennedy said, before commenting on shingles.

Pocan continued: “Polio?”

“Polio?” Kennedy said. “Again, I don’t want to be giving advice.”

The issued re-emerged in his afternoon testimony before the Senate committee on health, education, labor and pensions, where the Democrat Chris Murphy asked Kennedy if he would recommend the measles vaccine. The secretary demurred, prompting Murphy to say: “I think that’s really dangerous for the American public and for families.

“The secretary of health and human services is no longer recommending the measles vaccines,” Murphy said.

Kennedy’s hearing came at an exceptionally tumultuous period in America’s public health history. With help from the billionaire Elon Musk’s unofficial “department of government efficiency”, Kennedy has eliminated roughly 20,000 jobs, whole departments and expert public health labs. He has also in effect cut the federal biomedical and behavioral research budget by $2.7bn – including cancer research alone by 31% year-over-year – by failing to distribute or “impounding” funds.

Officially, the hearing was intended to investigate a White House budget proposal to cut tens of billions from the health department – slashing the federal government’s biomedical research arms in particular, the National Institutes of Health (NIH), by 40%.

However, it also took bizarre turns – as when Kennedy asserted that agencies would soon be “phasing out most animal studies” in favor of using artificial intelligence. The organic chemist and drug discovery researcher Derek Lowe described Kennedy’s claim as “bullshit”. He said such advances, while promising, were “years” away.

The White House budget has come alongside Republicans formally unveiling a “big, beautiful bill” to extend tax cuts from President Trump’s first term by in effect cutting federal healthcare subsidies. The Congressional Budget Office estimates that an additional 13.7 million Americans could become uninsured if the proposal moves forward.

The bill proposes adding work requirements to Medicaid and ending a federal subsidy for individual insurance through the Affordable Care Act (ACA), better known as “Obamacare”. Medicaid covers about 71 million low-income, disabled and elderly Americans – making it the largest health insurance program in the nation. This is Trump’s first attempt to restrict healthcare since 2017, when an attempt to repeal the ACA was dramatically tanked from within his own party.

Some Republicans are already wary of the bill, warning that taking away healthcare was, in the Missouri Republican senator Josh Hawley’s words, “morally wrong and politically suicidal”. Advocacy groups have also rallied to oppose the cuts.

“These work requirements and reporting requirements are designed to kick people off Medicaid,” said Julie Nickson, director of federal relations at the American Cancer Society Cancer Action Network. “And that’s what they’ll do.”

Even as Kennedy has eviscerated departments and fired workers, the health department has released few official details of the “reorganization” other than to claim that it would eliminate “fraud, waste and abuse”. Kennedy continued that pattern on Wednesday, as he told lawmakers he could not answer detailed questions about changes he has imposed.

“I’m going to talk very, very broadly … We are under a court order yesterday afternoon not to do any more planning under the reorganization, and I have been advised by my attorneys not to talk about it,” Kennedy said.

Lawrence Gostin, a global health law professor at Georgetown Law School called Kennedy’s assertions that the court order barred him from answering questions “pure nonsense”.

“The Department of Justice may be advising the secretary not to discuss the litigation,” said Gostin. “But the secretary has a public duty to explain the reasoning behind the reorganization of his department and to show why it is in the public interest.”

In addition to enormous and often untold cuts, Kennedy has also reinstated programs – Democrats argued based on political favor. For the first time, Kennedy commented on reinstatement of two branches of the National Institute for Occupational Health and Safety (Niosh) and the World Trade Center Health Program.

The programs researched and monitored miners for pneumoconiosis, better known as black lung, ran the firefighters’ national cancer registry and, paid for the healthcare of victims of the September 11 attacks.

“I reinstated 328 employees at Niosh – about a little over a third of them were in Morgantown and a third in Cincinnati and the WTC group,” Kennedy told Republican Riley Moore about programs in West Virginia and Ohio respectively.

The Connecticut Democrat Rosa DeLauro said: “I don’t understand why Republicans get to call you to spare offices like Niosh … Is there a special phone number if I want to save tobacco prevention, lead poisoning?” The Guardian